The Seattle-based medtech startup Proprio expects the Food and Drug Administration to approve its AR-platform Paradigm in H1 2023.  The six-year-old startup's Paradigm technology can improve surgery outcomes by helping surgeons identify where to insert incisions and place hardware.  More:  Following its approval, the company plans to commercially launch the program.  Paradigm uses high-def imaging technology to capture the operating room from above.  It then uses AI and augmented reality to combine those images with pre-surgery 3D imaging. These images then guide the doctor through surgery.  Proprio has several technology partners, including Intel, HTC, NVIDIA, Samsung, and the Paul G. Allen School of Computer Science at the University of Washington.